Inactief instrument

Andere talen Summit Therapeutics plc London S.E.

Aandelen

GB00BN40HZ01

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Sector Update: Health Care Stocks Steady Premarket Monday	03/06
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab	03/06
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab	03/06
Summit Therapeutics Inc. Expands License Territories for Ivonescimab	03/06
Summit Therapeutics Inc. announced that it expects to receive $199.999998 million in funding from Baker Bros. Advisors LP	03/06
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA	01/06
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy	01/06
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	31/05
Wall Street Set to Open Modestly Higher Friday as Key Inflation Data Meets Expectations	31/05
Sector Update: Health Care	31/05
US Futures Trend Modestly Lower Pre-Bell Friday as Investors Await Key Inflation Report	31/05
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/05
Health Care Stocks Steady -- Health Care Roundup	30/05
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival	30/05
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	30/05
Summit Therapeutics' Ivonescimab Beats Merck's Therapy in Lung Cancer -- Shares Soar	30/05
Summit Therapeutics Shares Triple After Drug Candidate Data	30/05
Summit Therapeutics cancer therapy succeeds in late-stage China study	30/05
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China	30/05
Summit Therapeutics Stock Trading Halted, Pending Material News Release	30/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Summit Therapeutics plc London S.E.

Aandelen

GB00BN40HZ01

Andere talen

Filters